查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493339

美國非酒精性脂肪性肝炎生物標記市場規模、佔有率和趨勢分析報告：按類型、最終用途和細分市場預測，2024-2030 年

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum, Hepatic Fibrosis, Apoptosis), By End-use (Hospitals, Diagnostic Labs), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格

美國非酒精性脂肪性肝炎生物標記市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，美國非酒精性脂肪性肝炎生物標記市場規模將達到28.4億美元，2024年至2030年複合年成長率為23.9%，預計將成長% 。

肥胖、2 型糖尿病和METABOLIC INC.症候群盛行率的增加導致美國人口中非酒精性脂肪性肝炎 (NASH) 的發生率不斷增加，從而推動了對生物標記的需求。根據美國國家醫學圖書館的數據，肝硬化和慢性肝病 (CLD) 是全球健康危害，每年導致 110 萬人死亡，使 CLD 成為全球第 11 大死因。

這個市場正在經歷重大的技術創新，重點是開拓新的生物標記，以準確診斷和監測 NASH（一種由脂肪堆積引起的肝臟疾病）。這些生物標記對於早期發現 NASH 患者、監測疾病進展和評估治療效果至關重要。公司和研究機構正在積極開發這些生物標記，以解決現有診斷工具的局限性，並提供有關疾病狀態的更準確的資訊。

行動應用程式、穿戴式裝置和人工智慧 (AI) 演算法等數位健康技術被用來開發用於 NASH 診斷和監測的新型生物標記。廣泛的臨床資料集的使用和人工智慧應用的最新進展為提高診斷準確性創造了巨大的潛力。 2023 年6 月，Kinetix 集團的NASHNET 卓越網路將回顧生物標記物在非酒精性脂肪性肝病(NAFLD) 和NASH 的診斷和分期方面的當前狀況和潛在的未來應用，我們已發布了一份探討該問題的白皮書。

美國非酒精性脂肪性肝炎生物標記市場報告亮點

  • 從類型來看，血清生物標記領域將在2023年以32.5%的銷售佔有率佔據市場主導地位。血清生物標記已成為醫療保健專業人員的重要工具，因為它們可以提供有關疾病進展和治療效果的寶貴見解。
  • 由於肥胖、久坐生活方式和METABOLIC INC.症候群的增加，預計肝纖維化生物標記在預測期內將以最快的速度成長。
  • 2023年，最終用途領域製藥和CRO產業主導市場。這一成長是由美國醫療保健支出和意識的增加所推動的，特別是對於慢性和複雜疾病。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章美國非酒精性脂肪性肝炎生物標記市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國非酒精性脂肪性肝炎生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國非酒精性脂肪性肝炎生物標記市場：類型估計和趨勢分析

  • 2023 年和 2030 年按類型分類的市場佔有率
  • 細分儀表板
  • 美國非酒精性脂肪性肝炎生物標記市場展望（按類型）
  • 2018-2030年市場規模、預測及趨勢分析
  • 血清生物標記
  • 肝纖維化生物標記
  • 細胞凋亡生物標記
  • 氧化壓力標誌物
  • 其他

第5章美國非酒精性脂肪性肝炎生物標記市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 美國非酒精性脂肪性肝炎生物標記市場前景（按最終用途）
  • 2018-2030年市場規模、預測及趨勢分析
  • 製藥/CRO產業
  • 醫院
  • 診斷實驗室
  • 學術研究所

第6章美國非酒精性脂肪性肝炎生物標記市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 美國非酒精性脂肪性肝炎生物標記市場：區域展望
  • 2018-2030年市場規模及預測趨勢分析：
    • 西
    • 中西部
    • 東北
    • 西南
    • 東南

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • GENFIT
    • Prometheus Laboratories
    • Siemens Medical Solutions USA, Inc.
    • Quest Diagnostics
    • AstraZeneca
    • Laboratory Corporation of America Holdings
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-282-9

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The U.S. non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 2.84 billion by 2030 and is anticipated to expand at a CAGR of 23.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome contribute to the growing incidence of non-alcoholic steatohepatitis (NASH) in the U.S. population, which is fueling the demand for biomarkers. According to the National Library of Medicine, Cirrhosis and chronic liver disease (CLD) are major worldwide health burdens leading to 1.1 million deaths yearly, and CLD ranks as the eleventh most common cause of death worldwide.

The market is experiencing significant innovation, primarily focused on developing novel biomarkers to accurately diagnose and monitor NASH, a liver disease caused by fat accumulation. These biomarkers are crucial for early detection, disease progression monitoring, and assessing treatment response in NASH patients. Companies and research institutions are actively developing these biomarkers to address the limitations of existing diagnostic tools and provide more accurate information about the disease status.

Digital health technologies such as mobile apps, wearable devices, and artificial intelligence (AI) algorithms are being used to develop novel biomarkers for NASH diagnosis and monitoring. The use of extensive clinical data sets and the latest advancements in AI applications have created a strong potential to increase diagnostic accuracy. In June 2023, the Kinetix Group's NASHNET network of excellence published a white paper that explored current perspectives and potential future applications of biomarkers for diagnosing and staging non-alcoholic fatty liver disease (NAFLD) and NASH.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

  • Based on the type, the serum biomarkers segment dominated the market with a revenue share of 32.5% in 2023. The ability of serum biomarkers to provide valuable insights into disease progression and treatment response has made them indispensable tools for healthcare professionals
  • The hepatic fibrosis biomarkers is expected to grow at the fastest rate during the forecast period due to the rising number of obesity, people following sedentary lifestyles, and metabolic syndromes
  • The pharma & CRO industry in end-use segment dominated the market in 2023. This growth is attributable to the increasing healthcare expenditure and awareness in the U.S., particularly for chronic and complex diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End-use
    • 1.2.3. Region
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. End-use Outlook
    • 2.2.3. Region Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Serum biomarkers
      • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Hepatic fibrosis biomarkers
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Apoptosis biomarkers
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4. Oxidative stress biomarkers
      • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.5. Others
      • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: End-use Estimates & Trend Analysis

  • 5.1. End-use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by End-use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Pharma & CRO industry
      • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2. Hospitals
      • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.3. Diagnostic labs
      • 5.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.4. Academic Research Institutes
      • 5.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by Region Outlook
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
    • 6.3.1. West
      • 6.3.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.2. Midwest
      • 6.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.3. Northeast
      • 6.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.4. Southwest
      • 6.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.3.5. Southeast
      • 6.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. GENFIT
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Prometheus Laboratories
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Siemens Medical Solutions USA, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Quest Diagnostics
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. AstraZeneca
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Laboratory Corporation of America Holdings
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Pfizer, Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Bristol-Myers Squibb Company
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. non-alcoholic steatohepatitis biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. non-alcoholic steatohepatitis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 U.S. non-alcoholic steatohepatitis biomarkers market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. non-alcoholic steatohepatitis biomarkers market: Market outlook
  • Fig. 9 U.S. non-alcoholic steatohepatitis biomarkers competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. non-alcoholic steatohepatitis biomarkers market driver impact
  • Fig. 14 U.S. non-alcoholic steatohepatitis biomarkers market restraint impact
  • Fig. 15 U.S. non-alcoholic steatohepatitis biomarkers market: Type movement analysis
  • Fig. 16 U.S. non-alcoholic steatohepatitis biomarkers market: Type outlook and key takeaways
  • Fig. 17 Serum biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Hepatic fibrosis biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Apoptosis biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Oxidative stress biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. non-alcoholic steatohepatitis biomarkers market: End-use movement analysis
  • Fig. 23 U.S. non-alcoholic steatohepatitis biomarkers market: End-use outlook and key takeaways
  • Fig. 24 Pharma & CRO industry market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Diagnostic labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Academic research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. non-alcoholic steatohepatitis biomarkers market: Regional movement analysis
  • Fig. 29 U.S. non-alcoholic steatohepatitis biomarkers market: Regional outlook and key takeaways
  • Fig. 30 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)